So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

A Delaware district court must maintain its pause of an order that the FDA delay final approval of MSN Laboratories Pvt. Ltd.

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs ...

MSN Laboratories Pvt. Ltd. is appealing rulings that block the early launch of its copy of Entresto and preserve Novartis ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 ...

Entresto was the company's top-selling product in 2023, generating sales of around $6B. MSN had been aiming to launch its ...

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily ...

NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...

Novartis AG raised its outlook for the year after profit beat estimates in the first quarter, driven by medicines for breast ...